Literature DB >> 2800994

Glycopyrrolate: pharmacokinetics and some pharmacodynamic findings.

T Ali-Melkkilä1, T Kaila, J Kanto.   

Abstract

In the present study, a sensitive and reproducible radioreceptor assay (RRA) was used to evaluate the basic pharmacokinetic properties of glycopyrrolate, a quaternary amine with peripheral antimuscarinic activity. Based on the plasma levels after a single intravenous injection, 6 micrograms/kg (n = 6), the distribution phase half-life (2.22 +/- 1.26 s.d. min) and the elimination phase half-life (0.83 +/- 0.29 h) of glycopyrrolate were short due to the low distribution volume during the elimination phase (0.64 +/- 0.29 l/kg) and to the respectively high total plasma clearance value (0.54 +/- 0.14 l/kg/h). An intramuscular injection, 8 micrograms/kg (n = 6), was followed by a fast and predictable systemic drug absorption and clinical effects (heart rate increase, dry mouth). In this group the time to maximum plasma concentration (tmax) was 27.48 +/- 6.12 min and the maximum plasma concentration (Cmax) was 3.47 +/- 1.48 micrograms/l. After oral drug intake, 4 mg (n = 6), an apparently low and variable gastrointestinal absorption was found (tmax = 300.0 +/- 197.2 min, Cmax = 0.76 +/- 0.35 microgram/l), thus indicating that the oral route of drug administration is of no value as a routine premedication. The correlation between the plasma concentration of glycopyrrolate and the drug effects appears to be variable. Because of its sensitivity, the RRA method proved to be quite useful in evaluating the kinetics of glycopyrrolate and its relationship to various clinical effects.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2800994     DOI: 10.1111/j.1399-6576.1989.tb02956.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  6 in total

1.  Glycopyrronium bromide blocks differentially responses mediated by muscarinic receptor subtypes.

Authors:  H Fuder; M Meincke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-06       Impact factor: 3.000

2.  Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach.

Authors:  Christian Bartels; Michael Looby; Romain Sechaud; Guenther Kaiser
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

3.  A case report: Glycopyrrolate for treatment of exercise-induced hyperhidrosis.

Authors:  Matthew Negaard; Christopher Anthony; Daniel Bonthius; Matthew Jepson; Britt Marcussen; Daniel Pelzer; Andrew Peterson
Journal:  SAGE Open Med Case Rep       Date:  2017-08-08

4.  Difficult Airway Society guidelines for awake tracheal intubation (ATI) in adults.

Authors:  I Ahmad; K El-Boghdadly; R Bhagrath; I Hodzovic; A F McNarry; F Mir; E P O'Sullivan; A Patel; M Stacey; D Vaughan
Journal:  Anaesthesia       Date:  2019-11-14       Impact factor: 6.955

5.  Hemodynamic and antiemetic effects of prophylactic hyoscine butyl-bromide during cesarean section under spinal anesthesia: a randomized controlled trial.

Authors:  Mostafa Samy Abbas; Shimaa Abbas Hassan; Ahmed Mohamed Abbas; Amr Mohamed Thabet; Ahmed Mostafa Thabet; Magdy Mohammed Mahdy
Journal:  BMC Anesthesiol       Date:  2022-04-21       Impact factor: 2.376

Review 6.  Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review.

Authors:  Werner Mendling; Ernst Rainer Weissenbacher; Stefan Gerber; Valdas Prasauskas; Philipp Grob
Journal:  Arch Gynecol Obstet       Date:  2015-10-27       Impact factor: 2.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.